Ypsomed Holding Ag · SIX:YPSN

Ypsomed — FY2025/26 Earnings Presentation

37 slides from Ypsomed's earnings presentation, May 20, 2026

  1. Slide 1: Ypsomed Full Year Results 2025/26

    Ypsomed Full Year Results 2025/26 Transforming selfcare, Transforming Ypsomed Zurich, 20 May 2026

  2. Slide 2: Important information

    Important information The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or op

  3. Slide 3: Making selfcare simpler and easier

    Making selfcare simpler and easier 3 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  4. Slide 4: We benefit from multiple structural growth drivers

    We benefit from multiple structural growth drivers  Selfcare Move from IV to subcutaneous delivery to enhance quality of life, encouraging therapy adherence and lower healthcare cost  Biologics Next generation drugs are mostly large molecules that must be injected  Biosimilars Expanding access to

  5. Slide 5: Ypsomed has completed its transformational journey to become a pure-play self-injection specialist

    Ypsomed has completed its transformational journey to become a pure-play self-injection specialist Ypsomed is now a pure-play self-injection specialist 2026 Phase-out of contract manufacturing delivery systems 2025 Completion of the sale of Ypsotec 2025 Completion of the sale of the diabetes care bu

  6. Slide 6: Thanks to its clear strategic focus, Ypsomed is uniquely positioned to continue to benefit from significant growth

    Thanks to its clear strategic focus, Ypsomed is uniquely positioned to continue to benefit from significant growth Operational Strong Platforms Innovation Excellence Financials 6 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  7. Slide 7: Ypsomed offers the broadest range of self-injection solutions on the market

    Ypsomed offers the broadest range of self-injection solutions on the market Operational Strong Platforms Innovation Excellence Financials 7 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  8. Slide 8: Ypsomed offers the broadest range of self-injection solutions on the market

    Ypsomed offers the broadest range of self-injection solutions on the market 8 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  9. Slide 9: Ypsomed won a record number of 44 new projects in FY 2025/26

    Ypsomed won a record number of 44 new projects in FY 2025/26, thereof 12 with new customers New project wins FY 2025/26 Ypsomed wins across the board Illustrative  Various therapeutic areas  Originators and biosimilars 44 new  Developed and emerging markets project  New and existing pharma custo

  10. Slide 10: Ypsomed has a diversified customer portfolio with no customer exceeding 15% of revenue

    Ypsomed has a diversified customer portfolio with no customer exceeding 15 % of revenue in the foreseeable future Commercial sales by customer FY 2025/26 Increasingly diversified portfolio Illustrative  >130 customers  No single customer accounts for more than 15 % of commercial revenue over 130 c

  11. Slide 11: Products approved

    Ypsomed supports patients with over 80 approved products in 25 indications Pens Autoinjectors  Osteoporosis  Diabetes  Asthma  Psoriasis  Fertility  Alzheimer  Rheumatoid Arthritis  Sexual dysfunction 80+  Growth Disorders  Atopic Dermatitis  Obesity  ATTR Amyloidosis  Hereditary Angioe

  12. Slide 12: Ypsomed is the innovation leader

    Ypsomed is the innovation leader Operational Strong Platforms Innovation Excellence Financials 12 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  13. Slide 13: We announced three new device platforms in FY 2025/26

    We announced three new devices platforms in FY 2025/26, all based on Ypsomed’s eco-design guidelines YpsoLoop won several awards CPHI Pharmapack innovation patient-centric award design award Red Dot product design award 13 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  14. Slide 14: Sustainability is embedded in Ypsomed's products, supply chain, and operations

    Sustainability is embedded in Ypsomed’s products, supply chain, and operations and cements our innovation leadership Eco-designed products Reduce dependencies Carbon-reduced Meet customer scope 3 supply chain requirements Less cost volatility and Energy-efficient sites improved bottom line 14 | Ypso

  15. Slide 15: Clear-to-Clinic accelerates time to market thanks to pre-validated platforms

    Clear-to-Clinic accelerates time to market thanks to pre-validated platforms Clinic-ready devices available in <6 months Documentation Verification Parallelization Early readiness 15 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  16. Slide 16: Ypsomed expands globally

    Ypsomed expands globally Operational Strong Platforms Innovation Excellence Financials 16 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  17. Slide 17: Ypsomed builds a global manufacturing footprint, producing local for local

    Ypsomed builds a global manufacturing footprint, producing local for local Holly Springs (USA) Schwerin (DE) Schwerin II (DE) opening 2027 opening 2026 Burgdorf HQ (CH) Solothurn (CH) Burgdorf (CH) Burgdorf (CH) Suzhou (CN) Changzhou (CN) (Contract Manuf.) 17 | Ypsomed Holding AG | Full year results

  18. Slide 18: In Solothurn we opened our new tool manufacturing facility in April 2026

    In Solothurn we opened our new tool manufacturing facility in April 2026 18 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  19. Slide 19: Phasing out Contract Manufacturing to focus on proprietary autoinjectors

    And we are phasing out Contract Manufacturing to focus on proprietary autoinjectors until end of 2026 19 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  20. Slide 20: In our Changzhou site commercial production has started end of 2025

    In our Changzhou site commercial production has started end of 2025 20 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  21. Slide 21: In Schwerin the extension is on track to open for first lines end of 2026

    In Schwerin the extension is on track to open for first lines end of 2026 21 | Ypsomed Holding AG | Full year results 2025/26

  22. Slide 22: Site in US, Holly Springs (NC), acquired and on track to open end of 2027

    Site in US, Holly Springs (NC), acquired and on track to open end of 2027 22 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  23. Slide 23: Number of employees

    Ypsomed created 245 jobs in the remaining business Delivery Systems 2 753  ~780 employees moved out with 548.5 2 249 2548.5 249 Diabetes Care divestment 2 099 2 099 744  ~140 employees moved to Preteq CNC Number of employees Solutions AG with sale of Ypsotec 1 854 Delivery Systems  For BY 2026/27

  24. Slide 24: Ypsomed delivered strong financial results

    Ypsomed delivered strong financial results Operational Strong Platforms Innovation Excellence Financials 24 | Ypsomed Holding AG | Full year results 2025/26 PUBLIC

  25. Slide 25: Financials reflect Ypsomed's successful transformation into a pure-play self-injection specialist

    Financials reflect Ypsomed's successful transformation into a pure-play self-injection specialist Sales by segment Delivery Systems is our core business FY 2025/26 in CHF million  Diabetes Care contributes 4 months of 56 sales, April to July 2025, prior to 75 divestment  Other includes mainly cont

  26. Slide 26: Delivery Systems grows around 20%

    Delivery Systems grows around 20 % Delivery Systems Sales Sustained growth trajectory 601 86 548. 5 +20 %  Strong commercial sales growth driven 88 501 by autoinjector growth, especially 515 YpsoMate 1.0 ml and 2.25 ml 413  Project revenue consists of in million CHF customization fees and clinical

  27. Slide 27: Delivery Systems operating income reached CHF 196 million

    Delivery Systems operating income reached CHF 196 million Reported EBIT Delivery Systems delivers ~33 % EBIT FY 2025/26 margin 246 56 –6  Strong profitability despite ramp up and 196 volume-based pricing  Other includes divestment one-offs for in million CHF Diabetes Care, Ypsotec, pen needle and

  28. Slide 28: Reported EBIT bridge FY 2024/25 to FY 2025/26

    Ypsomed reached a reported EBIT of CHF 246 million across all segments and including one-offs Reported EBIT bridge FY 2024/25 to FY 2025/26 56 -6 20 29 34 246 in million CHF 196 167 113 Diabetes Diabetes Systems Systems Systems Care Care Other 2024/25 Growth 2025/26 Other Delivery Delivery Delivery

  29. Slide 29: Focus on growth investments: Group Cash Flow

    Focus on growth investments Group Cash Flow Cash flow FY 2025/26  Strong operational cash flow growth -28 driven by Delivery Systems  Investing cash flow reflected significant capacity expansion investments, offset in million CHF 307 -287 279 by a cash inflow of CHF 307 million from the divestment

  30. Slide 30: Continued investments in infrastructure and R&D lay the foundation for future growth

    Continued investments in infrastructure and R&D lay the foundation for future growth Fixed assets expansion 202 295 28 323  YpsoMate and UnoPen 70 272  Across Switzerland, Germany, 80 201 the US, and China 202 in million CHF Intangible assets: R&D investment 121 Intangible assets  Next pen and au

  31. Slide 31: Ypsomed optimizes its investment program from CHF 1.5 billion to CHF 1.3 billion

    Ypsomed optimizes its investment program from CHF 1.5 billion to CHF 1.3 billion over the 6-year period, driven by efficiency gains Growth capex program  Flexible and modular manufacturing Illustrative, total fixed assets investments  20 % ROCE for Delivery Systems  Approved investment includes s

  32. Slide 32: Ypsomed's strong fundamentals and solid balance sheet allow us to fully fund our organic growth agenda

    Ypsomed's strong fundamentals and solid balance sheet allows us to fully fund our organic growth agenda CHF 232 million net debt as of 31 March 2026 CHF 278 million EBITDA Delivery Systems in 2025/26 ~0.8x net debt / EBITDA for Delivery Systems Ypsomed's strong balance sheet enables to fund own orga

  33. Slide 33: Ypsomed's business model provides meaningful downside resilience and strong topline visibility

    Ypsomed's business model provides meaningful downside resilience and strong topline visibility CHF Typical Indexation Capacity Majority of FDA contract for major reservation contracts Regulatory duration of cost blocks fee and in CHF Filling as ~10 years (plastic, volume- (natural FX combination ene

  34. Slide 34: YpsoFit, Ypsomed's operational excellence program

    YpsoFit, Ypsomed's operational excellence program – cementing margin resilience while enabling future growth Operations Stream- Accelerate Procurement efficiency line digitalization savings gains organization and leverage thanks to for faster AI larger orders decision & second making sourcing 34 | Y

  35. Slide 35: Delivery Systems outlook for FY 2026/27

    Delivery Systems outlook for the FY 2026/27, excluding phase-out contract manufacturing (CM) Delivery Systems Sales Phase-out 601 Guidance: 12−15 % sales growth EBIT CHF 210−230 million in million CHF 559 EBIT margin >33 % 2025/26 2026/27 Note: Guidance is provided for Delivery Systems excluding CM,

  36. Slide 36: Ypsomed is well-positioned to deliver robust growth until the end of the decade and beyond

    Ypsomed is well-positioned to deliver robust growth until the end of the decade and beyond Net Sales Mid-term ambition (FY 2029/30) Illustrative  CHF 0.9−1.1 billion sales in Delivery Systems (midpoint 15 % CAGR)  CHF 280−340 million EBIT (not less than 30 % EBIT margin) Note: Graph is purely conc

  37. Slide 37: We look forward to your questions.

    We look forward to your questions.

Ypsomed Holding — FY2025/26 Earnings Presentation on 6ix